My Crossword Maker Logo
Powered by BrightSprout
Save Status:
or to save your progress. The page will not refresh.
Controls:
SPACEBAR SWITCHES TYPING DIRECTION
Answer Key:
Edit a Copy:
Make Your Own:
Crossword Word Search Worksheet
Rate This Puzzle:
Log in or sign up to rate this puzzle.

Top 20 US Oncology Labs Puzzle:2018 Annual Reports Edition

If you need extra clues, contact Michael Farmer at [email protected].
Across
#2 cancer reference lab in the US, and #1 west of the Rockies.
Our CEO is really good at buying labs at fire-sale prices. He made GE look dumb in 2015, then he made Novartis look dumb last October.
This NGS oncology lab's revenues were up 50% last year, from $65m to nearly $100m.
We turn stool specimens into $500 invoices. We did that 934,000 times last year.
We're the #3 cancer reference lab in the US, near the Rock and Roll Hall of Fame
Very few people know how big we are, because our ≈100 pathologists each bill under their own name. We did 400,000+ primary stains last year.
We had one foot in the grave, then in December this Australian knight in shining armor showed up
We took in more money for NGS testing than any other lab in the world last year.
We're the Walmart of NGS testing, and our revenues doubled in 2018.
Down
Our prognostic assays save a lot of drug money, so payors are glad to give us $3,600 per specimen.
Our 42 anatomic labs did 2.5m primary stains in 2018.
Last year we were #3 overall in US IVD testing, and #11 in oncology.
We're the #1 reference lab in the US.
We are currently the heavyweight champ of liquid biopsies, with $80m in 2018 revenues.
We operate the two busiest single histology labs on Earth. What's our new name?
Drug companies just love to throw money at us:20,000+ pharma tests at $6,000+ each in 2018.
We did 30,000 thyroid FNAs last year and got $2,900 per patient for them.
Our 46 anatomic labs took in $650m last year
Our founder had the biggest NGS-earned income tax bill in history in 2018, after his $400m+ paycheck in 2017.
G'Day Mate. We were #10 in US oncology revenues in 2018, but we acquired #7, so now we're #4.